NCT04196205 is a Phase 1, PHASE2 clinical trial of Anti-CD19 CAR-T in Acute Lymphoblastic Leukemia ,Lymphomas, sponsored by The First Affiliated Hospital of Nanchang University.

Who is sponsoring NCT04196205?

NCT04196205 is sponsored by The First Affiliated Hospital of Nanchang University.

What drugs are being tested in NCT04196205?

Interventions in NCT04196205: Anti-CD19 CAR-T.

What condition does NCT04196205 study?

NCT04196205 studies Acute Lymphoblastic Leukemia ,Lymphomas.

Is NCT04196205 still recruiting?

NCT04196205 is currently status unknown. Last updated 12 December 2019.

Last reviewed 2019-12-12 · How we verify

NCT04196205

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

Status unknown Phase 1, PHASE2 Last updated 12 December 2019

What this trial tests

Phase 1, PHASE2 trial testing Anti-CD19 CAR-T in Acute Lymphoblastic Leukemia ,Lymphomas in 20 participants. Status unknown.

Timeline

1 December 2019

Primary endpoint
1 August 2020

1 August 2021

Quick facts

Lead sponsor	The First Affiliated Hospital of Nanchang University
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 December 2019
Primary completion	1 August 2020
Estimated completion	1 August 2021
Sites	1 location across China

Drugs / interventions tested

Anti-CD19 CAR-T

Conditions studied

Acute Lymphoblastic Leukemia ,Lymphomas — all drugs for Acute Lymphoblastic Leukemia ,Lymphomas →

Sponsor

The First Affiliated Hospital of Nanchang University

Who can join

Adults 18 to 70, any sex, with Acute Lymphoblastic Leukemia ,Lymphomas. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm, open-label, single center study to determine the safety and efficacy of Anti-CD19 CAR-T cells in patients with relapsed or refractory acute lymphoblastic leukemia and Lymphomas.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other The First Affiliated Hospital of Nanchang University trials

Trials by the same sponsor.

NCT06639516 — Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Co · NA · not yet recruiting
NCT07136961 — Efficacy and Safety of Robotic-assisted Bronchoscopy Combined With the ICNVA Strategy in Biopsy of Peripheral Pulmonary · NA · active not recruiting
NCT06999031 — A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma · EARLY_PHASE1 · recruiting
NCT06751966 — Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment · NA · recruiting
NCT06752057 — Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04196205 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Nanchang University
Last refreshed: 12 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04196205.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing